Loading...

LEXX LEXARIA BIOSCIENCE CORP Investments/Divestments 8-K Filing

LXR

LXX

LEXARIA BIOSCIENCE CORP

(LEXX)

2024 8-K

Show Summary

Show Summary

Product Expansion

Equity Offerings

Sales Agreement Update

Shareholder Meeting

Management Change

Project Agreement

Director Nominations

Management Change

Stock Sale Agreement

Resignation of CFO and Init...

Warrant Exercise Agreement

Annual Shareholder Meeting

Amendment of Material Defin...

Appointment of CFO

FDA Approval for Clinical T...

Securities Purchase Agreement

IND Application for Hyperte...

Regulation FD Disclosure

Compliance and Warrant Exer...

Shareholder Meeting and Oth...

Securities Purchase Agreement

Licensing Amendment and New...

New Product Launches

Management Changes

Entry into a Material Defin...

Investment Offering

Annual Shareholder Meeting

Regulation FD Disclosure

External Links:

Lexaria Bioscience Corp. announced the final results from its human pilot study on the GLP-1 drug semaglutide, showing that the DehydraTECH processed dosage had higher blood levels and reduced side effects compared to the control sample.

AI Assistant

LEXARIA BIOSCIENCE CORP

2024

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.